Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer's Disease has been accepted for two presentations at AAIC.
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Longeveron prices $5.15 million public offering with certain board member and insider participation.
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (Longeveron or Company), a clinical stage biotechnology company developing regenerative medicines for unmet medical...
Layoffs are in store for employees at both Longeveron and Nicox, although neither company is spelling out how many staff will be affected.
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B„¢ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B„¢ in HLHS Continues Enrollment; Completion of...